DOI: https://doi.org/10.22141/2224-0713.2.96.2018.130482

Contemporary ideas about pathogenesis and treatment of anxiety disorders

O.O. Copchak

Abstract


The review of the literature presents modern data on the peculiarities of epidemiology, clinical picture, pathophysiological mechanisms and potential biomarkers of anxiety disorders. Current approaches to the treatment of anxiety disorders are described.


Keywords


anxiety disorders; features of etiopathogenesis; treatment; reviews

References


Abdallah C.G., Coplan J.D., Jackowski A. et al. A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD // Eur. Neuropsychopharmacol. — 2013. — 23(4). — P. 276-284.

Andreatini R., Sartori V.A., Seabra M.L., Leite J.R. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study // Phytother. Res. — 2002. — 16(7). — P. 650-654.

Baldwin D.S., Ajel K., Masdrakis V.G., Nowak M., Rafiq R. Pregabalin for the treatment of generalized anxiety disorder: an update // Neuropsychiatr. Dis. Treat. — 2013. — 9. — P. 883-892.

Bandelow B., Baldwin D., Abelli M. et al. Biological markers for anxiety disorders, OCD and PTSD — a consensus statement. Part I: neuroimaging and genetics // World J. Biol. Psychiatry. — 2016. — 17(5). — P. 321-365.

Bandelow B., Baldwin D., Abelli M. et al. Biological mar­kers for anxiety disorders, OCD and PTSD: a consensus statement. Part II: neurochemistry, neurophysiology and neurocognition // World J. Biol. Psychiatry. — 2017. — 18(3). — P. 162-214.

Bandelow B., Chouinard G., Bobes J. et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study // Int. J. Neuropsychopharmacol. — 2010. — 13(3). — P. 305-320.

Bandelow B., Lichte T., Rudolf S., Wiltink J., Beutel M.E. The diagnosis of and treatment recommendations for anxiety disorders // Dtsch. Arztebl. Int. — 2014. — 111(27–28). — P. 473-480.

Bandelow B., Michaelis S. Epidemiology of anxiety disorders in the 21st century // Dialogues Clin. Neurosci. — 2015. — 17(3). — P. 327-335.

Bandelow B., Michaelis S., Wedekind D. Treatment of anxiety disorders // Dialogues in Clinical Neuroscience. — 2017. — 19(2). — P. 93-106.

Bandelow B., Reitt M., Rover C. et al. Efficacy of treatments for anxiety disorders: a meta-analysis // Int. Clin. Psychopharmacol. — 2015. — 30(4). — P. 183-192.

Bankier B., Barajas J., Martinez-Rumayor A., Januzzi J.L. Association between C-reactive protein and generalized anxiety disorder in stable coronary heart disease patients // Eur. Heart J. — 2008. — 29(18). — P. 2212-2217.

Cipriani A., Furukawa T.A., Salanti G. et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis // Lancet. — 2009. — 373(9665). — P. 746-758.

Connolly K.R., Thase M.E. Emerging drugs for major depressive disorder // Expert. Opin. Emerging. Drugs. — 2012. — Vol. 17(1). — P. 105-126.

Cooper A.J., Narasimhan S., Rickels K., Lohoff F.W. Genetic polymorphisms in the PACAP and PAC1 receptor genes and treatment response to venlafaxine XR in generalized anxiety disorder // Psychiatry Res. — 2013. — 210(3). — P. 1299-1300.

Cooper A.J., Rickels K., Lohoff F.W. Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder // Hum. Psychopharmacol. — 2013. — 28(3). — P. 258-262.

Copeland W.E., Shanahan L., Worthman C. et al. Genera­lized anxiety and C-reactive protein levels: a prospective, longitudinal analysis // Psychol. Med. — 2012. — 42(12). — P. 2641-2650.

Cuijpers P., Sijbrandij M., Koole S., Huibers M. et al. Psychological treatment of generalized anxiety disorder: a meta-analysis // Clin. Psychol. Rev. — 2014. — 34(2). — P. 130-140.

Cusack B., Nelson A., Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds // Psychopharmacology. — 1994. — Vol. 114. — P. 559-564.

Etkin A., Prater K.E., Schatzberg A.F. et al. Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder // Arch. Gen. Psychiatry. — 2009. — 66(12). — P. 1361-1372.

Fu J., Peng L., Li X. The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-ana­lysis // Neuropsychiatr. Dis. Treat. — 2016. — 12. — P. 951-959.

Generalised anxiety disorder and panic disorder in adults: management National Institute for Health and Care Excellence. — London: NICE, 2011.

Hilbert K., Pine D.S., Muehlhan M. et al. Gray and white matter volume abnormalities in generalized anxiety disorder by categorical and dimensional characterization // Psychiatry Res. — 2015. — 234(3). — P. 314-320.

Hofmann S.G., Asnaani A., Vonk I.J., Sawyer A.T., Fang A.

The efficacy of cognitive behavioral therapy: A review of meta-analyses // Cognitive therapy and research. — 2012. — 36(5). — P. 427-440.

Jacobs B.P., Bent S., Tice J.A., Blackwell T., Cummings S.R.

An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia // Medicine (Baltimore). — 2005. — 84(4). — P. 197-207.

Kasper S., Anghelescu I., Dienel A. Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep — a randomized, placebo-controlled trial // Eur. Neuropsychopharmacol. — 2015. — 25(11). — P. 1960-1967.

Kasper S., Gastpar M., Muller W.E. et al. Lavender oil preparation Silexan is effective in generalized anxiety disorder — a randomized, double-blind comparison to placebo and paroxetine // Int. J. Neuropsychopharmacol. — 2014. — 17(6). — P. 859-869.

Kasper S., Herman B., Nivoli G. et al. Efficacy of pregabalin and venlafaxine XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial // Int. Clin. Psychopharmacol. — 2009. — 24(2). — P. 87-96.

Kasper S., Volz H.P., Dienel A., Schlafke S. Efficacy of Silexan in mixed anxiety-depression — a randomized, placebo-controlled trial // Eur. Neuropsychopharmacol. — 2016. — 26(2). — P. 331-340.

Kessler R.C., Berglund P., Demler O. et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication // Arch. Gen. Psychiatry. — 2005. — 62(6). — P. 593-602.

Khan A., Joyce M., Atkinson S. et al. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder // J. Clin. Psychopharmacol. — 2011. — 31(4). — P. 418-428.

Khazaie H., Resaie L., Payam N.R., Najafi F. Antidepressant — induced sexual dysfunction during treatment with fluoxetine, sertraline and trazodone; a randomized controlled trail // General Hospital Psychiatry. — 2015. — 37. — 40-45.

Koh K.B., Lee B.K. Reduced lymphocyte proliferation and interleukin-2 production in anxiety disorders // Psychosom. Med. — 1998. — 60(4). — P. 479-483.

Li X., Zhu L., Su Y., Fang S. Short-term efficacy and tolerability of venlafaxine extended release in adults with genera­lized anxiety disorder without depression: A meta-analysis // PLoS ONE. — 2017. — 12(10): e0185865.

Lohoff F.W., Aquino T.D., Narasimhan S. et al. Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder // Pharmacogenomics J. — 2013. — 13(1). — P. 21-26.

Lohoff F.W., Narasimhan S., Rickels K. Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder // Pharmacogeno­mics J. — 2013. — 13(5). — P. 464-469.

Makovac E., Meeten F., Watson D.R. et al. Neurostructural abnormalities associated with axes of emotion dysregulation in generalized anxiety // Neuroimage Clin. — 2015. — 10. — P. 172-181.

Maron E., Nutt D. Biological markers of generalized anxiety disorder // MedSci Dialogues Clin. Neurosci. — 2017. — 19. — P. 147-157.

Mathew S.J., Mao X., Coplan J.D. et al. Dorsolateral prefrontal cortical pathology in generalized anxiety disorder: a proton magnetic resonance spectroscopic imaging study // Am. J. Psychiatry. — 2004. — 161(6). — P. 1119-1121.

Molendijk M.L., Bus B.A., Spinhoven P. et al. Gender specific associations of serum levels of brain-derived neurotrophic factor in anxiety // World J. Biol. Psychiatry. — 2012. — 13(7). — P. 535-543.

Monk C.S., Telzer E.H., Mogg K. et al. Amygdala and ventrolateral prefrontal cortex activation to masked angry faces in children and adolescents with generalized anxiety disorder // Arch. Gen. Psychiatry. — 2008. — 65(5). — P. 568-576.

Moon C.M., Jeong G.W. Abnormalities in gray and white matter volumes associated with explicit memory dysfunction in patients with generalized anxiety disorder // Acta Radiol. — 2017. — 58(3). — 353-361.

Moon C.M., Jeong G.W. Alterations in white matter volume and its correlation with clinical characteristics in patients with ge­neralized anxiety disorder // Neuroradiology. — 2015. — 57(11). — P. 1127-1134.

Moon C.M., Kang H.K., Jeong G.W. Metabolic change in the right dorsolateral prefrontal cortex and its correlation with symptom severity in patients with generalized anxiety disorder: proton magnetic resonance spectroscopy at 3 Tesla // Psychiatry Clin. Neurosci. — 2015. — 69(7). — P. 422-430.

Moreira F.P., Fabião J.D., Bittencourt G. et al. The Met allele of BDNF Val66Met polymorphism is associated with increased BDNF levels in generalized anxiety disorder // Psychiatr. Genet. — 2015. — 25(5). — P. 201-207.

Morrissette D.A., Stahl S.M. Modulating the serotonin system in the treatment of major depressive disorder — ERRATUM // NS Spectr. — 2015. — 20(4). — P. 452-3.

Muscatello M.R., Spina E., Bandelow B., Baldwin D.S. Clinically relevant drug interactions in anxiety disorders // Hum. Psychopharmacol. — 2012. — 27(3). — P. 239-253.

Narasimhan S., Aquino T.D., Hodge R. et al. Association analysis between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and treatment response to venlafaxine XR in generalized anxiety disorder // Neurosci Lett. — 2011. — 503(3). — P. 200-202.

Narasimhan S., Aquino T.D., Multani P.K. et al. Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder // Psychiatry Res. — 2012. — 198(1). — P. 112-115.

Newman M.G., Llera S.J., Erickson T.M., Przeworski A., Castonguay L.G. Worry and generalized anxiety disorder: a review and theoretical synthesis of evidence on nature, etiology, mechanisms, and treatment // Annu Rev. Clin. Psychol. — 2013. — 9. — P. 275-97.

Pae C.U., Wang S.M., Han C. et al. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis // J. Psychiatr. Res. — 2015. — 64. — P. 88-98.

Pallanti S., Tofani T., Zanardelli M. et al. BDNF and Artemin are increased in drug-naїve non-depressed GAD patients: preliminary data // Int. J. Psychiatry Clin. Pract. — 2014. — 18(4). — P. 255-260.

Perlis R.H., Fijal B., Dharia S., Houston J.P. Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder// Pharmacogenomics J. — 2013. — 13(3). — P. 280-285.

Rubio G., Lopez-Ibor J.J. Generalized anxiety disorder: a 40-year follow-up study // Acta Psychiatr Scand. — 2007. — 115(5). — P. 372-379.

Rubio G., Lopez-Ibor J.J. What can be learnt from the natural history of anxiety disorders? // Eur. Psychiatry. — 2007. — 22(2). — P. 80-86.

Schienle A., Ebner F., Schifer A. Localized gray matter volume abnormalities in generalized anxiety disorder // Eur. Arch. Psychiatry Clin. Neurosci. — 2011. — 261(4). — P. 303-307.

Schweizer E., Rickels K., De Martinis N., Case G., Garcia-Espana F. The effect of personality on withdrawal severity and taper outcome in benzodiazepine dependent patients // Psychol. Med. — 1998. — 28(3). — P. 713-720.

Stahl S.M., Lee-Zimmerman C., Cartwright S., Morrissette D.A. Serotoninergic drugs for depression and beyond // Curr. Drug Targets. — 2013. — 14(5). — P. 578-85.

Stahl S.M. Mechanism of action of trazodone: a multifunctional drug // CNS Spectr. — 2009. — Vol. 14. — P. 536-46.

Steudte-Schmiedgen S., Wichmann S., Stadler T. et al. Hair cortisol concentrations and cortisol stress reactivity in generalized anxiety disorder, major depression and their comorbidity // Journal of psychiatric research. — 2017. — 84. — P. 184-190.

Thanacoody H.K., Thomas S.H. Tricyclic antidepressant poisoning: cardiovascular toxicity // Toxicol. Rev. — 2005. — 24(3). — P. 205-214.

Tiihonen J., Kuikka J., Rаsаnen P. et al. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis // Mol. Psychiatry. — 1997. — 2(6). — P. 463-471.

Tofani T., Mannelli L.D., Zanardelli M. et al. An immunologic profile study in drug-naive generalized anxiety non depressed patients: a pilot study // Eur. Neuropsychopharmacol. — 2015. — 25 (suppl. 2). — S226.

Woelk H., Schlafke S. A multi-center, double-blind, randomised study of the lavender oil preparation Silexan in comparison to lorazepam for generalized anxiety disorder // Phytomedicine. — 2010. — 17(2). — P. 94-99.

World Health Organization. ICD-10 Chapter V (F) Classification of Mental and Behvioural Disorders: Clinical Descriptions and Diagnostic Guidelines // “Blue Book” Clinical Descriptions and Diagnostic Guidelines. — Geneva, Switzerland: World Health Organization, 1991.

Yoshinaga N., Matsuki S., Niitsu T. et al. Cognitive beha­vioral therapyfor patients with social anxiety disorder who remain symptomatic following antidepressant treatment: a randomized, assessor-blinded, controlled trial // Psychother. Psychosom. — 2016. — 85(4). — P. 208-217.

Zou C., Ding X., Flaherty J.H., Dong B. Clinical efficacy and safety of fluoxetine in generalized anxiety disorder in Chinese patients // Neuropsychiatr. Dis. Treat. — 2013. — 9. — P. 1661-70.




Copyright (c) 2018 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2019

 

   Seo анализ сайта